Project Grant R41HL184694
Award Date 8/1/26
Completion Date 1/31/28
Dollars Obligated $217K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
South Euclid, OH 44121, USA
Similar Awards
- Federal Project Grant Award Summary Perfusion Solutions Inc. received a $320,838 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 5, 2025, with completion targeted for February 28, 2027. The award supports Phase I development of a fail-safe, high-output cavopulmonary assist pump designed for pediatric and congenital heart disease patients with single ventricle physiology...
- The National Heart, Lung, and Blood Institute awarded Corvion, Inc. $2,999,968 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a novel pediatric left ventricular assist device (P-LVAD) enabling children with end-stage heart failure to discharge home while awaiting heart transplantation or living long-term with the device. This is a Project Grant (SBIR Phase II). Corvion will engineer an implantable, ultra-low-power blood pump combining hydrodynamic...
- Percassist Inc. received a $663,129 Project Grant award from the National Heart Lung and Blood Institute of the Department of Health and Human Services. The award was made under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. The grant funds the development of a percutaneous ventricular assist device for chronic heart failure patients. Specifically, Percassist will design and test a balloon catheter implant that can be delivered minimally...
- The National Heart, Lung, and Blood Institute awarded the Research Institute At Nationwide Children's Hospital $3.147 million on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop surgical strategies improving long-term outcomes after Fontan surgery in children with single ventricle disease. The project addresses the long-term complications of the Fontan operation, a palliative surgical procedure that remains the standard of care for single ventricle...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded The Leland Stanford Junior University $163,160 on February 10, 2027, under the Cardiovascular Diseases Research program (CFDA 93.837) to optimize Fontan creation and failing Fontan ventricular assist device (VAD) implementation using patient-specific computational flow modeling and ex-vivo 4D-flow MRI cardiac simulation. The recipient will develop and validate patient-specific computational models testing hepatic flow distributions...
- The National Heart, Lung, and Blood Institute awarded Starlight Cardiovascular, Inc. $499,952 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 10, 2026, to advance commercialization of a catheter-delivered, adjustable percutaneous pulmonary flow restrictor designed to replace surgical pulmonary artery banding in newborns with hypoplastic left heart syndrome and other congenital heart defects. The flow restrictor addresses clinical limitations of current surgical...
- The National Heart, Lung, and Blood Institute awarded Inflo Medical Inc. $595,332 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to optimize its MOBYBOX extracorporeal membrane oxygenation (ECMO) platform for pediatric use. Inflo Medical is redesigning the MOBYBOX's gas exchanger and pulsatile displacement pump to reduce thrombogenicity and hemolysis in pediatric patients. The Phase I Small Business Innovation Research effort focuses on two complementary...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $767,953 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop biomimetic engineered heart valve leaflets that improve function and tissue remodeling. Work extends through March 31, 2030, and is performed in Pittsburgh, Pennsylvania. The project addresses clinical failures in tissue-engineered heart valves (TEHVs) deployed in pediatric patients, where pulmonary...
- The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...
- The National Heart, Lung, and Blood Institute awarded $775,114 to the Research Institute At Nationwide Children's Hospital on June 12, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct preclinical evaluation of a cell-free tissue-engineered vascular graft designed for congenital heart surgery. The research addresses complications arising from prosthetic biomaterials currently used in surgical repair of complex congenital cardiac anomalies, including thromboembolic...